Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd

Share Article

Genetic Rx Boston

“The Genetic Rx Conference gathers many of the stakeholders in these pioneering efforts to discuss progress and challenges in this endeavor.”

Prominent academics, leaders of the biopharmaceutical industry and key investors will gather on December 3rd at Genetic Rx, a networking conference of the Boston Biotech Conferences series. GeneticRx will take place at the Joseph B. Martin Conference Center at Harvard Medical School and will discuss the present and future of genetic medicines—including siRNA, ASOs, LNAs, gene therapy, exon skipping, and gene editing—as well as the treatment of patients with rare and ultra-rare genetic diseases.

Speakers include Katrine Bosley (Editas), George Church (Harvard Medical School), Iain Dukes (Merck), Doug Fambrough (Dicerna), Chris Garabedian (Sarepta), Kathy High (Children's Hospital of Philadelphia), Richard Geary (Isis), Douglas Kerr (Biogen), Richard Moscicki (FDA) and Phil Sharp (MIT), among others. Leading investors from Bain Capital, Wellington Management Company, Pioneer Investments, Deerfield Partners, Fidelity Investments, Sofinnova Ventures, and Third Rock Ventures will also be in attendance.

“It’s increasingly clear that future innovative medicines for the treatment of many diseases will come in the form of genetic therapies such as oligonucleotides, gene therapy, exon skipping and gene editing, amongst other approaches,” says John Maraganore, Ph.D., CEO of Alnylam Pharmaceuticals, Inc. “The Genetic Rx Conference gathers many of the stakeholders in these pioneering efforts to discuss progress and challenges in this endeavor.”

JC Gutierrez-Ramos, Group SVP for Worldwide R&D at Pfizer, says of the event: “In this conference, we will immerse ourselves in the medicine of the future.”

For more information, please click here.

ABOUT THE BOSTON BIOTECH CONFERENCES (BBC)

The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of bio-pharma leaders, which will help to drive innovation in biotech, and bring important drugs to patients more quickly. The conferences are exclusive, thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the bio-pharma community. The meetings are invitation-only, off-the-record forums that bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information, or to register, visit http://www.bbbiotechconference.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cristina Ojeda
@BiotechConf
since: 01/2010
Follow >
Boston Biotech Conferences
since: 05/2012
Like >
Visit website